Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s disease
The DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Abstract
The novel antibiotic-exploiting strategy in the treatment of Alzheimer's (AD) and Parkinson's (PD) disease has emerged as a potential breakthrough in the field. The research in animal AD/PD models provided evidence on the antiamyloidogenic, anti-inflammatory, antioxidant and antiapoptotic activity of tetracyclines, associated with cognitive improvement. The neuroprotective effects of minocycline and doxycycline in animals initiated investigation of their clinical efficacy in AD and PD patients which led to inconclusive results and additionally to insufficient safety data on a long-standing doxycycline and minocycline therapy in these patient populations. The safety issues should be considered in two levels; in AD/PD patients (particularly antibiotic-induced alteration of gut microbiota and its consequences), and as a world-wide threat of development of bacterial resistance to these antibiotics posed by a fact that AD and PD are widespread incurable diseases which require daily administered long-lasting antibiotic therapy. Recently proposed subantimicrobial doxycycline doses should be thoroughly explored for their effectiveness and long-term safety especially in AD/PD populations. Keeping in mind the antibacterial activity-related far-reaching undesirable effects both for the patients and globally, further work on repurposing these drugs for a long-standing therapy of AD/PD should consider the chemically modified tetracycline compounds tailored to lack antimicrobial but retain (or introduce) other activities effective against the AD/PD pathology. This strategy might reduce the risk of long-term therapy-related adverse effects (particularly gut-related ones) and development of bacterial resistance toward the tetracycline antibiotic agents but the therapeutic potential and desirable safety profile of such compounds in AD/PD patients need to be confirmed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Generally, although promising, two main concerns remain about the use of antibiotics in PD treatment: (i) antibiotics can kill some specific microbial populations leading to intestinal dysbiosis and neurological dysfunction and (ii) their prolonged and widespread intake would favor antibiotic resistance [213,300,301].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [301]
In the citing paper
“Generally, although promising, two main concerns remain about the use of antibiotics in PD treatment: (i) antibiotics can kill some specific microbial populations leading to intestinal dysbiosis and neurological dysfunction and (ii) their prolonged and widespread intake would favor antibiotic resistance [213,300,301].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [301]
Citations
Cites
1 retracted
Items 201–261 of 261
Lucchetti, J., Fracasso, C., Balducci, C., Passoni, A., Forloni, G., Salmona, M., & Gobbi, M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252064 · Cited by 75
Margolis, D. J., Hoffstad, O., & Bilker, W. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08056.x · Cited by 74 · cited 1×
“Studies have found that the risk of developing lupus was greater after a total of 300 days of use or exposure to more than 50,000 mg of the drug, and that it often required treatment (Margolis et al. 2007).”
BackgroundThe neuroprotective effect of doxycycline on neurodegenerative diseases
Santa-Cecília, F. V., Leite, C. A., Del-Bel, E., & Raisman-Vozari, R. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00015-z · Cited by 73
GSK3-mediated raptor phosphorylation supports amino-acid-dependent mTORC1-directed signalling
Stretton, C., Hoffmann, T. M., Munson, M. J., Prescott, A., Taylor, P. M., Ganley, I. G., & Hundal, H. S. (2015) · Biochemical Journal · doi:10.1042/bj20150404 · Cited by 72 · cited 1×
“IR-PI3K/Akt pathway further targets multiple downstream pathways including the glycogen synthase kinase-3 (GSK3), which beside other roles, regulates the intraneuronal glucose uptake, homeostasis od tau protein phosphorylation and processing of amyloid beta precursor protein (Ma 2014), and mammalian target of rapamyci…”
BackgroundRepurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
Yimer, E. M., Hishe, H. Z., & Tuem, K. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00236 · Cited by 72 · cited 1×
“2013; Kaeberlein and Galvan 2019), extensive investigations of tetracyclines as possible new ND-modifying drugs have been initiated (Balducci and Forloni 2019; Molloy et al. 2013; Yimer et al. 2019; Yulug et al. 2018).”
BackgroundTeo, E., Ravi, S., Barardo, D., Kim, H.-S., Fong, S., Cazenave-Gassiot, A., Tan, T. Y., Ching, J., Kovalik, J.-P., Wenk, M. R., et al. (2019) · eLife · doi:10.7554/elife.50069 · Cited by 72
Tetracycline Actions Relevant to Rosacea Treatment
Korting, H. C., & Schöllmann, C. (2009) · Skin Pharmacology and Physiology · doi:10.1159/000235550 · Cited by 71 · cited 2×
“2015; Korting and Schöllmann 2009).”
BackgroundKeijmel, S. P., Delsing, C. E., Bleijenberg, G., van der Meer, J. W. M., Donders, R. T., de Jager-Leclercq, M. G. L., Kampschreur, L. M., van den Berg, M., Sprong, T., Nabuurs-Franssen, M. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix013 · Cited by 68
Do selected drugs increase the risk of lupus? A matched case‐control study
Schoonen, W. M., Thomas, S. L., Somers, E. C., Smeeth, L., Kim, J., Evans, S., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03733.x · Cited by 66 · cited 1×
“Drug-induced lupus among those with acne is more common among users of minocycline and in young females (Schoonen et al. 2010; Sturkenboom et al. 1999).”
BackgroundNeuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
Orsucci, D., Calsolaro, V., Mancuso, M., & Siciliano, G. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709788680689 · Cited by 66
GSK3 in Alzheimer's Disease: Mind the Isoforms
Ma, T. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131661 · Cited by 66
Amani, M., Shokouhi, G., & Salari, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5137-8 · Cited by 64
Minocycline protects basal forebrain cholinergic neurons from mu p75‐saporin immunotoxic lesioning
Hunter, C. L., Quintero, E. M., Gilstrap, L., Bhat, N. R., & Granholm, A. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03439.x · Cited by 63 · cited 2×
“2006), while 1/5 study used non-transgenic rats treated intracerebroventricularly with an immunotoxin p75-saporin (Hunter et al. 2004) and 1/5 study used both transgenic mice and non-transgenic rat model induced by a central administration of Aβ1–42 (Choi et al.”
BackgroundTetracycline prevents Aβ oligomer toxicity through an atypical supramolecular interaction
Airoldi, C., Colombo, L., Manzoni, C., Sironi, E., Natalello, A., Doglia, S. M., Forloni, G., Tagliavini, F., Favero, E. D., Cantú, L., et al. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00303d · Cited by 63
Azevedo, E. P., Ledo, J. H., Barbosa, G., Sobrinho, M., Diniz, L., Fonseca, A. C. C., Gomes, F., Romão, L., Lima, F. R. S., Palhano, F. L., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.325 · Cited by 62 · cited 1×
“Three-day pretreatment with minocycyline was capable of preventing memory deficits and reversing neuroinflammation in mice model of OA induced by intracerebroventricular injection of amyloid fibrils composed of A25T TTR but no direct effect on TTR was detected (Azevedo et al. 2013).”
BackgroundTetracyclines and Prion Infectivity
Forloni, G., Salmona, M., Marcon, G., & Tagliavini, F. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/1871526510909010023 · Cited by 62
Search for Alzheimer's Disease Biomarkers in Blood Cells: Hypotheses-Driven Approach
Wojsiat, J., Laskowska-Kaszub, K., Mietelska-Porowska, A., & Wojda, U. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0041 · Cited by 61
Cai, Z., Yan, & Wang (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s46536 · Cited by 60
Socías, S. B., González‐Lizárraga, F., Ávila, C. L., Vera, C., Acuña, L., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Chehín, R. N. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.002 · Cited by 60 · cited 3×
“On the other hand, it has been speculated that since the trials were performed with patients diagnosed with AD, amyloid oligomeric species were probably already formed before the treatment with minocycline and rifampine was initiated, which, according to the in vitro studies, could account for the minocycline failure…”
BackgroundResultChen, S.-D., Yin, J.-H., Hwang, C.-S., Tang, C.-M., & Yang, D.-I. (2012) · Free Radical Research · doi:10.3109/10715762.2012.674640 · Cited by 59
Forloni, G., Tettamanti, M., Lucca, U., Albanese, Y., Quaglio, E., Chiesa, R., Erbetta, A., Villani, F. S., Redaelli, V., Tagliavini, F., et al. (2015) · Prion · doi:10.1080/19336896.2015.1027857 · Cited by 59
Quintero, E. M., Willis, L., Singleton, R., Harris, N., Huang, P., Bhat, N., & Granholm, A.-C. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.104 · Cited by 58
Antibiotic Use and the Risk of Lung Cancer
Zhang, H., Rodríguez, L. A. G., & Hernández–Díaz, S. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2817 · Cited by 57 · cited 1×
“1 3 of receiving an antibiotic prescription (Bartlett 2004; Friedman et al. 2006; Zhang et al. 2008).”
BackgroundThomas, J. G., Metheny, R. J., Karakiozis, J. M., Wetzel, J., & Crout, R. J. (1998) · Advances in Dental Research · doi:10.1177/08959374980120011601 · Cited by 57
Cuello, A. C., Ferretti, M. T., Leon, W. C., Iulita, M. F., Melis, T., Ducatenzeiler, A., Bruno, M. A., & Canneva, F. (2010) · Neurodegenerative Diseases · doi:10.1159/000285514 · Cited by 54
Soter, A. C., Bezerra, T. F. P., Pezato, R., Abdo, T. R. T., Pilan, R. R. D. M., Pinna, F. R., Gevaert, P., Zele, T. V., Bachert, C., & Voegels, R. L. (2017) · Rhinology Journal · doi:10.4193/rhino15.291 · Cited by 51
Sinha, M. S., Bhowmick, P., Banerjee, A., & Chakrabarti, S. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.036 · Cited by 50 · cited 1×
“It acts like an antioxidant in physiological conditions by blocking the formation of hydroxyl radicals and thus preventing protein and lipid oxidation in mitochondria (Sinha et al. 2013).”
BackgroundImpact of minocycline on neurodegenerative diseases in rodents: a meta-analysis
Li, C., Yuan, K., & Schluesener, H. (2013) · revneuro · doi:10.1515/revneuro-2013-0040 · Cited by 50 · cited 3×
“However, literature data outside of the meta-analysis of Li and coworkers (Li et al. 2013) demonstrated that short-term treatment with a low minocycline dose (10 mg/kg i.”
BackgroundDefining the limits: Protein aggregation and toxicity in vivo
Holmes, W. M., Klaips, C. L., & Serio, T. R. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.914151 · Cited by 49
Mendes, R. E., Farrell, D. J., Sader, H. S., Streit, J. M., & Jones, R. N. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.12.011 · Cited by 48
Margolis, D. J. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2011.355 · Cited by 45 · cited 1×
“In these studies of college students, once again it was noticed that those exposed to antibiotics for acne were three times more likely to report upper respiratory tract infections (Margolis et al. 2012).”
BackgroundInflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight
Forloni, G., Vitola, P. L., Cerovic, M., & Balducci, C. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.11.001 · Cited by 45
Chtarto, A., Humbert-Claude, M., Bockstael, O., Das, A. T., Boutry, S., Breger, L. S., Klaver, B., Melas, C., Barroso-Chinea, P., Gonzalez-Hernandez, T., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.27 · Cited by 43
Liu, H., Su, W., Li, S., Du, W., Ma, X., Jin, Y., Li, K., & Chen, H. (2017) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2017.07.003 · Cited by 43
In search of an anti-inflammatory drug for Alzheimer disease
Gyengesi, E., & Münch, G. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0307-9 · Cited by 43
Doxycycline 40 mg Capsules (30 mg Immediate-Release/10 mg Delayed-Release Beads)
McKeage, K., & Deeks, E. D. (2010) · American Journal of Clinical Dermatology · doi:10.2165/11204850-000000000-00000 · Cited by 42 · cited 1×
“…plasma concentrations of approximately 1.7–5.9 µg/ml (Agwuh and MacGowan 2006) and dose of 40 mg/day produces a plasma concentration around 0.2–0.5 µg/ml (Mckeage and Deeks 2010) while in rats treated chronically with oral doses of 75 and 200 mg/ kg, detected drug plasma concentration was on…”
BackgroundInfluentialWang, N., Tian, X., Chen, Y., Tan, H.-Q., Xie, P.-J., Shao-jun, C., Fu, Y., Chen, Y., Xu, W., & Wei, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14408-7 · Cited by 42 · cited 1×
“Low doxycycline doses were more effective than high doses in modulating gene expression of lipopolisaccharide-induced pro-inflammatory cytokines (IL-8, TNFα, and IL-6) in immortalized human keratinocytes (Wang et al. 2017).”
BackgroundKeerthisinghe, T. P., Wang, M., Zhang, Y., Dong, W., & Fang, M. (2019) · Environment International · doi:10.1016/j.envint.2019.104989 · Cited by 41
Gautieri, A., Beeg, M., Gobbi, M., Rigoldi, F., Colombo, L., & Salmona, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184641 · Cited by 41
Impairment of mitochondrial function by minocycline
Kupsch, K., Hertel, S., Kreutzmann, P., Wolf, G. L., Wallesch, C.-W., Siemen, D., & Schönfeld, P. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.06904.x · Cited by 39 · cited 1×
“At low micromolar concentrations minocycyline impairs several energy-dependent functions of mitochondria in vitro (Kupsch et al. 2009).”
BackgroundSun, C., Wang, Y., Mo, M., Song, C., Wang, X., Chen, S., & Liu, Y. (2019) · BioMed Research International · doi:10.1155/2019/6843265 · Cited by 37 · cited 3×
“and Pseudomonas aeruginosa foreshadowed the increasing clinical resistance to latest-generation tetracycline antibiotics (Gasparrini et al. 2020; Sun et al. 2019).”
BackgroundInfluentialClinical trials of prion disease therapeutics
Forloni, G., Roiter, I., & Tagliavini, F. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.019 · Cited by 37
Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity
Medina, L., González‐Lizárraga, F., Dominguez‐Meijide, A., Ploper, D., Parrales, V., Sequeira, S., Cima‐Omori, M., Zweckstetter, M., Bel, E. A. D., Michel, P. P., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.635760 · Cited by 35
Mozafari, H., Amiri, S., Mehr, S. E., Momeny, M., Amini-Khoei, H., Bijani, S., & Hosseini, M.-J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05696-w · Cited by 34
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33 · cited 2×
“In vivo study in a rat 6-OHDA model of PD reported that CMT-3/COL-3 attenuated L-DOPA-induced dyskinesia in a rat 6-OHDA model of PD without affecting the improved motor response after L-DOPA treatment (Bortolanza et al. 2021).”
BackgroundThe Disposition of Doxycycline by the Rat
von Wittenau, M. S., Twomey, T. M., & Swindell, A. C. (2009) · Chemotherapy · doi:10.1159/000220836 · Cited by 30
Anti-apoptotic effects of minocycline on ram epididymal spermatozoa exposed to oxidative stress
Merati, Z., Farshad, A., Farzinpour, A., Rostamzadeh, J., & Sharafi, M. (2018) · Theriogenology · doi:10.1016/j.theriogenology.2018.03.041 · Cited by 30
Barilar, J. O., Knezović, A., Perhoč, A. B., Homolak, J., Riederer, P. F., & Šalković‐Petrišić, M. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02152-8 · Cited by 24
CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
González‐Lizárraga, F., Ploper, D., Ávila, C. L., Socías, S. B., Pereira, M. D. S., Machín, B., Bel, E. A. D., Michel, P. P., Pietrasanta, L. I., Raisman‐Vozari, R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76927-0 · Cited by 23
Rao, V., Nagaraj, R. K., Hebbagodi, S., Kadarinarasimhiah, N. B., & Kakkar, V. V. (2010) · Cardiology Research and Practice · doi:10.4061/2011/295976 · Cited by 22
Chalmers, J. R., Wojnarowska, F., Kirtschig, G., Mason, J. M., Childs, M., Whitham, D., Harman, K. E., Chapman, A., Walton, S., Schmidt, E., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21100 · Cited by 22
Increase in Viral Gastroenteritis Outbreaks in Europe and Epidemic Spread of New Norovirus Variant
(2004) · Infectious Diseases in Clinical Practice · doi:10.1097/01.idc.0000130890.12611.f3 · Cited by 22
Minocycline differentially modulates human spatial memory systems
Berens, S. C., Bird, C. M., & Harrison, N. A. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00811-8 · Cited by 21
Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients
B�cker, R., M�hlberg, W., Platt, D., & Estler, C. ‐. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00614205 · Cited by 20
Tetracycline derivatives resist the assembly behavior of human islet amyloid polypeptide
Xu, J., Zhao, C., Huang, X., & Du, W. (2020) · Biochimie · doi:10.1016/j.biochi.2020.04.012 · Cited by 19
Garrett, J. P.-D., & Margolis, D. J. (2012) · Current Dermatology Reports · doi:10.1007/s13671-011-0001-7 · Cited by 17 · cited 1×
“Although these patients are much younger than patients with NDs, most of the observed side effects can be expected in the elderly patient population as well (Garrett and Margolis 2012).”
BackgroundWang, Y., Wang, Q., Yu, R., Zhang, Q., Zhang, Z., Li, H., Ren, C., Yang, R., & Niu, H. (2020) · Aging · doi:10.18632/aging.103440 · Cited by 17
Mining Endonuclease Cleavage Determinants in Genomic Sequence Data
Szeto, M. D., Boissel, S., Baker, D. A., & Thyme, S. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.259572 · Cited by 15 · cited 1×
“The effects of minocycline in CD4+ T cells were associated with its impact on the activity of the transcription factors like NF-κB, AP-1 (activator protein 1), and NFAT (nuclear factor of activated T cells) as well as with attenuation of intracellular Ca2+ levels (Szeto et al. 2011).”
BackgroundLessons learned from protein aggregation: toward technological and biomedical applications
Ávila, C. L., Chaves, S., Socías, S. B., Pingitore, E. V., González‐Lizárraga, F., Vera, C., Ploper, D., & Chehín, R. N. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0317-z · Cited by 15 · cited 13×
“Experiments in mice expressing a mutant superoxide dismutase (SOD1G37R) and mimicking human ALS, demonstrated that daily administration of minocycline (1 g/kg) into the diet, initiated at late presymptomatic stage (7 or 9 months of age), delayed the onset of motor neuron degeneration, muscle strength decline, and incr…”
BackgroundInfluentialLavigna, G., Masone, A., Bouybayoune, I., Bertani, I., Lucchetti, J., Gobbi, M., Porcu, L., Zordan, S., Rigamonti, M., Imeri, L., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105455 · Cited by 14 · cited 16×
“The facts that tetracycline resembles to iododoxorubicin and the ability of the latter drug to produce clinical benefits in patients with immunoglobulin light-chain amyloidosis initiated the research on the efficacy of tetracycline in preventing the pathological aggregation and propagation of PrP among 1 3 the first s…”
BackgroundInfluentialDoxycycline promotes proteasome fitness in the central nervous system
Jenkins, E. C., O’Connell, M. J., Manfredi, G., & Germain, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-96540-z · Cited by 8
Research works printed but not linked: 8
- Beauduy CEWL (2018) Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, & oxazolidinones. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw Hill-Education, New York, pp 815–825
- Erekat NS (2018) Apoptosis and its role in Parkinson’s disease. In: Stoker TB, Greenland JC (eds) Parkinson’s disease: pathogenesis and clinical aspects, chapter 4. Codon Publications, Brisbane
- Forloni G, Salmona M, Marcon G et al (2012) Tetracyclines and prion infectivity. Infect Disord Drug Targets 9(1):23–30. https://doi.org/10.2174/1871526510909010023 · DOI · Paper page
- Holmes C (2017) Inflammation in Alzheimer’s disease. In: Ames D, O’Brien JT, Burns A (eds) Dementia, 5th edn. CRC Press, Boca Raton
- Ian C, Marilyn R (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65(3):232–260. https://doi.org/10.1128/MMBR.65.2.232 · doi:10.1128/mmbr.65.2.232
- Kempuraj D, Thangavel R, Natteru PA et al (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1(1):1003
- Perdue BE, Standiford HC (1999) Tetracyclines. In: Yu VL, Merigan TC, Barriere SL (eds) Antimicrobial therapy and Vaccines. Williams and Wilkins, Baltimore, p 981
- Tong M, Dong M, De La Monte SM (2009) Brain Insulin-like growth factor and neurotrophin resistance in parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis 16(3):585–599. https://doi.org/10.3233/JAD-2009-0995.Brain · doi:10.3233/jad-2009-0995.brain
Cited by
Qin, J., Ma, Z., Chen, X., & Shu, S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1103416 · Cited by 207
“The fact that AD/PD patients (especially the changes of intestinal flora caused by antibiotics and their consequences), as well as AD and PD are universal incurable diseases that require long-term antibiotic treatment every day, constitutes a worldwide threat of bacterial resistance to these antibiotics (147).”
BackgroundVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 56
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 43
Serebrovska, Z. O., Xi, L., Tumanovska, L. V., Shysh, A. M., Goncharov, S. V., Khetsuriani, M., Kozak, T. O., Pashevin, D. O., Dosenko, V., Virko, S. V., et al. (2022) · Life · doi:10.3390/life12030432 · Cited by 34
“Recent studies have underscored an anti-inflammatory and/or antioxidant therapeutic approach to reducing the rate of development of the main AD symptoms [25,26].”
Background
Metadata
- Authors
- Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M.
- Affiliations
- University Hospital Centre Zagreb (HR)
- Venue
- Journal of Neural Transmission
- Published
- 2022-01-04
- Volume
- 129
- Issue
- 5-6
- Pages
- 773-804
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W4205398889
- Cited by
- 36
- References
- 261
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 7 · 2023: 7 · 2022: 4
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Regional Development Fund (GA KK01.1.1.01.0007)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tetracycline, drug repurposing, Alzheimer's disease, Parkinson's disease, minocycline, doxycycline, antibiotic resistance, gut microbiota, neuroprotection, chemically modified tetracyclines
- MeSH terms
- Alzheimer Disease, Animals, Anti-Bacterial Agents, Doxycycline, Humans, Minocycline, Parkinson Disease, Tetracycline, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.